Vertex announces long-term access agreement in Sweden for CF medicine ORKAMBI
Vertex announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and county councils. June 18, 2018